2 High-Yield Healthcare Stocks to Buy Before They Raise Payouts

AbbVie yields 3.3% and Medtronic yields 3.7%, both well above the S&P 500's 1.1% average, underscoring their appeal as income stocks. AbbVie is already a Dividend King with a $1.73 quarterly payout raised in April, while Medtronic has logged 48 consecutive annual increases and last raised its dividend in May 2025 to $0.71 per share. The article is bullish on both companies' dividend durability, but it is largely commentary and unlikely to materially move shares.

Analysis

The market is treating these as simple yield stories, but the more interesting angle is durability of capital return under slower top-line growth. ABBV’s setup is stronger because its cash generation is increasingly diversified away from any single asset, which reduces the probability that dividend growth becomes hostage to one molecule’s decay curve. That matters because high-yield healthcare names tend to re-rate when investors gain confidence that payout growth can persist through the next 2-3 years, not just the next quarter.

MDT is the cleaner quality income name, but its catalyst path is different: the bull case is not explosive growth, it’s multiple expansion if management proves that margin discipline can offset sluggish device volumes. The second-order winner here may be Abbott (ABT) and other diversified med-tech peers, because a stronger read-through on dividend resilience in large-cap healthcare can raise the sector’s floor multiple and compress the relative appeal of lower-yield, lower-growth cash return names.

The real risk is that both names are being bought for yield at a time when falling rates could temporarily mask deteriorating operating momentum. If Treasury yields back up, these stocks can de-rate quickly because their dividend premium is partly a duration trade. For ABBV, the key failure mode is any sign that post-Humira mix shift is not enough to sustain double-digit FCF conversion; for MDT, it’s any evidence that volume growth is still too weak to support an imminent dividend-King narrative.

Consensus is probably underpricing the asymmetry in ABBV versus MDT. ABBV has more embedded optionality from pipeline and acquisition synergies, while MDT is more of a bond proxy with modest upside unless execution improves. That makes ABBV the better “own on weakness” name and MDT more suitable as a defensive relative-value position rather than an outright momentum trade.

Key Decisions for Investors

• Long ABBV on a 3-6 month horizon into dividend-raise season; target a low-teens total return with downside cushioned by ~3%+ yield and improving cash-flow visibility.
• Initiate a relative-value long ABBV / short XLU or long ABBV / short MDT pair if rates stabilize; ABBV should outperform the lower-growth bond-proxy profile by 5-10% over the next 1-2 quarters.
• Buy MDT only on a pullback or after confirmation of operating inflection; otherwise treat it as a hold for income, not a catalyst-driven upside name.
• For portfolio defense, consider a covered-call overlay on MDT over the next 1-2 earnings cycles to monetize low expected growth while retaining dividend carry.
• If 10-year yields rise meaningfully, reduce exposure to both names; the yield thesis becomes less compelling and multiple compression can offset 1-2 years of dividend income.